We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+33.86%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
+$1.05B
Cap. Flow
-$233M
Cap. Flow %
-3.6%
Top 10 Hldgs %
39.98%
Holding
155
New
25
Increased
25
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$249M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$112M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$71.9M
4
ENDP
Endo International plc
ENDP
+$58M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$53M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$259M
2
BIIB icon
Biogen
BIIB
+$235M
3
AGN
Allergan plc
AGN
+$128M
4
CVS icon
CVS Health
CVS
+$52M
5
CNC icon
Centene
CNC
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Financials 1.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
26
Puma Biotechnology
PBYI
$398M
$72.9M 1.13%
1,880,000
-718,883
-28% -$22M
BOLD
27
DELISTED
Audentes Therapeutics, Inc
BOLD
$70.8M 1.1%
1,815,000
-78,500
-4% -$2.25M
ILMN icon
28
Illumina
ILMN
$29.3B
$70.6M 1.09%
233,664
-19,121
-8% -$5.58M
CLVS
29
DELISTED
Clovis Oncology, Inc.
CLVS
$70.3M 1.09%
2,832,300
+80,100
+3% +$2.01M
EXEL icon
30
Exelixis
EXEL
$14.1B
$66.7M 1.03%
2,801,900
– –
A icon
31
Agilent Technologies
A
$39.5B
$64.2M 0.99%
798,700
+45,700
+6% +$3.47M
TEVA icon
32
Teva Pharmaceuticals
TEVA
$39.4B
$64M 0.99%
+4,079,000
New +$71.9M
LOGC
33
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$63.9M 0.99%
6,466,783
– –
PTCT icon
34
PTC Therapeutics
PTCT
$6.2B
$57.2M 0.89%
1,519,700
– –
BMY icon
35
Bristol-Myers Squibb
BMY
$130B
$57M 0.88%
1,195,000
+689,100
+136% +$34.3M
HUM icon
36
Humana
HUM
$43.8B
$55.9M 0.87%
210,300
+3,800
+2% +$1.1M
IOVA icon
37
Iovance Biotherapeutics
IOVA
$2.04B
$52.8M 0.82%
5,548,326
– –
AVDR
38
DELISTED
Avedro, Inc Common Stock
AVDR
$52M 0.81%
+4,240,128
New +$53M
ENDP
39
DELISTED
Endo International plc
ENDP
$49.5M 0.77%
+6,165,464
New +$58M
ABT icon
40
Abbott
ABT
$191B
$49.2M 0.76%
615,400
+167,000
+37% +$12.4M
MYOK
41
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$47.1M 0.73%
906,600
+571,500
+171% +$26.3M
ARGX icon
42
argenx
ARGX
$55.3B
$45.1M 0.7%
361,300
-286,300
-44% -$33.7M
CRNX icon
43
Crinetics Pharmaceuticals
CRNX
$8.88B
$43.6M 0.67%
1,914,282
– –
MGTX icon
44
MeiraGTx Holdings
MGTX
$1.08B
$42.4M 0.66%
2,460,251
+1,990,298
+424% +$28M
ZLAB icon
45
Zai Lab
ZLAB
$2.06B
$41.4M 0.64%
1,401,318
-352,220
-20% -$9.64M
CI icon
46
Cigna
CI
$78.8B
$40.6M 0.63%
252,600
-230,100
-48% -$42M
TNDM icon
47
Tandem Diabetes Care
TNDM
$1.23B
$40.1M 0.62%
631,300
-316,700
-33% -$16.6M
ARVN icon
48
Arvinas
ARVN
$530M
$39.5M 0.61%
2,678,810
– –
VRAY
49
DELISTED
ViewRay, Inc.
VRAY
$38.1M 0.59%
5,149,019
– –
ONC
50
BeOne Medicines Ltd
ONC
$34B
$37.3M 0.58%
282,500
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2019 Portfolio in Review

As of Q1 2019, OrbiMed held 155 positions worth $6.46B, up 19% from $5.41B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $233M in Q1 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Alector worth $247M.

  • OrbiMed's largest Q1 2019 buy was Alector: 13,182,329 shares worth $247M.
  • OrbiMed added most to Neurocrine Biosciences in Q1 2019, an estimated $112M increase.
  • OrbiMed's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $259M.
  • OrbiMed fully exited Allergan plc in Q1 2019, selling an estimated $128M.
  • OrbiMed's ten largest holdings make up 40% of its $6.46B portfolio in Q1 2019.
  • OrbiMed opened 25 new positions and closed 31 in Q1 2019.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.